<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Referred-in-Senate" bill-type="olc" dms-id="HBAC53B55451842C6B77536E887952BAD" public-private="public" stage-count="1">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 3537 : Dangerous Synthetic Drug Control Act of 2016</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2016-09-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">IIB</distribution-code>
		<congress display="yes">114th CONGRESS</congress>
		<session display="yes">2d Session</session>
		<legis-num>H. R. 3537</legis-num>
		<current-chamber display="yes">IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action><action-date date="20160927">September 27, 2016</action-date><action-desc>Received; read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc></action><legis-type>AN ACT</legis-type>
		<official-title display="yes">To amend the Controlled Substances Act to add certain synthetic substances to schedule I, and for
			 other purposes.</official-title>
	</form>
	<legis-body display-enacting-clause="yes-display-enacting-clause" id="H238DD8F0787E4CF0B5637B5DAD20B9C6" style="OLC">
 <section id="HB93F5F406E2F4137A5EB58A9150D8027" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Dangerous Synthetic Drug Control Act of 2016</short-title></quote>.</text> </section><section id="H457E013B092949D4A4D5F40465F69A7F"><enum>2.</enum><header>Treatment of certain designer drugs as schedule I controlled substances</header> <subsection id="H8E208CE7D57E4C23B010DAB1BE93EC3C"><enum>(a)</enum><header>Cannabimimetic agents</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (d)(2)(B)—</text>
 <paragraph id="H88305BFCF1934930B603AB2A35DCB20B"><enum>(1)</enum><text>in clause (xiv) by striking <quote>and</quote> at the end;</text> </paragraph><paragraph id="H0B4E3BC4D3F44B89A63090EF20EE16B9"><enum>(2)</enum><text>in clause (xv) by striking the period and inserting a semicolon; and</text>
 </paragraph><paragraph id="HBE09711DB97B4FA8B87C39387E49963D"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H19F44FFB483A40B0B059882A72D761BE" style="OLC"> <clause id="HE0EC2227742340F3813B2AAFB293E2B1" indent="up1"><enum>(xvi)</enum><text>2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–251);</text>
 </clause><clause id="H4C25A23B94DA4151948F2DB461C139A6" indent="up1"><enum>(xvii)</enum><text>(1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone (4′-methyl JWH–073);</text> </clause><clause id="HB660868BB9034C6D94DF62FA29158B8D" indent="up1"><enum>(xviii)</enum><text>2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone (JWH–302);</text>
 </clause><clause id="H15CB4468771D4B5783124E538055E6C1" indent="up1"><enum>(xix)</enum><text>N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (5F–APICA);</text> </clause><clause id="H2AD11332F000415E8651268EE4E95376" indent="up1"><enum>(xx)</enum><text>quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F–PB–22);</text>
 </clause><clause id="H28123DA510154B21B0E35BE95F1C4033" indent="up1"><enum>(xxi)</enum><text>N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA);</text> </clause><clause id="HD38919E5D5EF4422A782065374A2AB36" indent="up1"><enum>(xxii)</enum><text>N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide (MN–24);</text>
 </clause><clause id="HBAE90A16E9BB404EAFFC5B97A988EC99" indent="up1"><enum>(xxiii)</enum><text>(1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ–2201);</text> </clause><clause id="H4D68FA6193E54DA99436B78C840B3ED0" indent="up1"><enum>(xxiv)</enum><text>N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADBICA);</text>
 </clause><clause id="HB5A8750EFA064F96A69479D1AB57EE8C" indent="up1"><enum>(xxv)</enum><text>methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (5F–AMB); and</text> </clause><clause id="H1B9FFF1D86254B979264021BE40DB186" indent="up1"><enum>(xxvi)</enum><text>methyl 2-(1-(cyclohexylmethyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (MA–CHMINACA).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H8E1AF5484BE94560AEAE54629B0C02C8"><enum>(b)</enum><header>Synthetic opioids</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (a) by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H7D58061FC0214329910062D2AB781ABA" style="OLC">
 <paragraph id="H39DA98D40E244C4D91C74601A7D197E5"><enum>(43)</enum><text>Butyryl fentanyl.</text> </paragraph><paragraph id="HFF64C1FF68B541EBB07D91825AAAD996"><enum>(44)</enum><text>beta-Hydroxythiofentanyl.</text>
 </paragraph><paragraph id="H1EE39D9E77EC4643A857D359963053EA"><enum>(45)</enum><text>Acetyl fentanyl.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="H2F6F3BD9BE314A688A0F5BC1C3C1257B"><enum>(c)</enum><header>Other drugs</header><text>Schedule I, as set forth in section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>), is amended in subsection (c) by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="HF5CE02E418874D7AAB90141CD6E99940" style="OLC">
 <paragraph id="H80C102376F0B474396A6BB3A61B5AAE3"><enum>(29)</enum><text>1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one (α-naphyrone).</text> </paragraph><paragraph id="H4FCA730C9E054F03B735C7DF3F0E1E8B"><enum>(30)</enum><text>1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine (5–APDB).</text>
 </paragraph><paragraph id="H85CEBFF23543492C8904869A65AA24B9"><enum>(31)</enum><text>1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine (6–APDB).</text> </paragraph><paragraph id="H708A2A183AF94B869914A42FD6F6F1A7"><enum>(32)</enum><text>6,7-dihydro-5H-indeno[5,6-d][1,3]dioxol-6-amine (MDAI).</text>
 </paragraph><paragraph id="H51EE89F280FF40FF875733756BA3DFBF"><enum>(33)</enum><text>5-iodo-2,3-dihydro-1H-inden-2-amine (5–IAI).</text> </paragraph><paragraph id="H9634F9E6DB0B44449A2C6FF2420D11FA"><enum>(34)</enum><text>1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-amine (bromo-dragonfly).</text>
 </paragraph><paragraph id="H26F77EB163454C98BC1C9CF3F31F4122"><enum>(35)</enum><text>1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine (DOC).</text> </paragraph><paragraph id="H23F22C508F81477ABB15B6ED0F4BC927"><enum>(36)</enum><text>1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine (MEM).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section></legis-body>
	<attestation><attestation-group><attestation-date chamber="House" date="20160926">Passed the House of Representatives September 26, 2016.</attestation-date><attestor display="yes">Karen L. Haas,</attestor><role>Clerk.</role></attestation-group></attestation>
</bill>


